Home Featured Page 120

Featured

Latest

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics

Psychedelic Research Bulletin: January 2023

PT389 – The Art of Ecstasy: The 90’s British Club Scene...

Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team...

Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit...

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023...

FILAMENT HEALTH ANNOUNCES SECOND PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR...

Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Psychedelics Weekly – AIMS vs. the DEA: An Update on the...

Establishing the Psychedelic Research Center Consortium

EDITOR PICKS

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

Film Club: Music for Mushrooms

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care

test

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics

Psychedelic Research Bulletin: January 2023

PT389 – The Art of Ecstasy: The 90’s British Club Scene...

Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team...

Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit...

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023...

FILAMENT HEALTH ANNOUNCES SECOND PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR...

Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Psychedelics Weekly – AIMS vs. the DEA: An Update on the...

Establishing the Psychedelic Research Center Consortium

EDITOR PICKS

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

test

Film Club: Music for Mushrooms

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY